PTC Therapeutics, Inc.
PTCT
$75.25
-$0.92-1.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 17.96% | -84.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.96% | -84.79% | |||
| Cost of Revenue | -6.81% | 2.11% | |||
| Gross Profit | 74.55% | -94.83% | |||
| SG&A Expenses | -1.43% | 5.31% | |||
| Depreciation & Amortization | 85.52% | 6.92% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.91% | 3.46% | |||
| Operating Income | 110.01% | -103.60% | |||
| Income Before Tax | 67.53% | -107.64% | |||
| Income Tax Expenses | -528.24% | -109.80% | |||
| Earnings from Continuing Operations | 124.51% | -107.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 124.51% | -107.48% | |||
| EBIT | 110.01% | -103.60% | |||
| EBITDA | 153.52% | -102.79% | |||
| EPS Basic | 124.42% | -107.48% | |||
| Normalized Basic EPS | 55.92% | -107.61% | |||
| EPS Diluted | 123.51% | -108.27% | |||
| Normalized Diluted EPS | 60.29% | -108.42% | |||
| Average Basic Shares Outstanding | 0.41% | 0.05% | |||
| Average Diluted Shares Outstanding | 11.47% | -9.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||